v3.26.1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 26, 2026
Apr. 01, 2025
Aug. 28, 2023
Jun. 30, 2023
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Fair value         $ 43,300   $ 43,300   $ 176,500
Unrealized gain (loss)             (200)   $ 100
Debt securities mature within one year         76,200   76,200    
Debt securities mature within year one through five         38,600   38,600    
Estimated proceeds from sale of priority review voucher $ 150,000                
Proceeds from sale of PRV   $ 148,300         0 $ 150,000  
Inventory write-down         0 $ 11,700 485 $ 11,681  
Reported Value Measurement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Unrealized gain (loss)             (100)    
Amortized cost         $ 71,500   $ 71,500    
License | XOMA License Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Regulatory milestone payment       $ 4,000          
Sales milestone payment       5,000          
Annual sales       $ 100,000          
Acer and Relief Therapeutics SA | License | Relief Termination Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Royalty percentage     10.00%            
Contractual obligation     $ 45,000            
Acer and Relief Therapeutics SA | License | Relief Termination Agreement | Maximum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contractual obligation     $ 56,500